Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care
Evidence-based guidelines in Australia recommend that women consider taking selective oestrogen receptor modulators (SERMs) to reduce their risk of breast cancer. For those in practice, this requires effective methods to communicate the harms and benefits of taking SERMs in order for women to make an informed choice. This study lead by PC4 researcher Dr Jennifer McIntosh aimed to evaluate how different risk presentations influence women’s decisions to consider taking SERMs. The findings suggested that specific risk presentation formats may lead to more women considering SERMs to reduce their risk of breast cancer – particularly in those who are at high risk of the condition, as well as that Raloxifene in particular may be a more acceptable SERM to patients.